On November 27, 2019 Medivir AB reported that Interim Result January – September 2019 (Press release, Medivir, NOV 27, 2019, View Source;interim-report-january—september-2019-300966014.html [SID1234551768]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Financial summary
Net turnover amounted to SEK 1.7 (3.0) million.
The loss before interest, tax, depreciation and amortization (EBITDA) totaled SEK -22.0 (-66,9) million. Basic and diluted earnings per share amounted to SEK -0.95 (-2.93) SEK and SEK -0.95 (-2.93) respectively.
Cash flow from operating activities amounted to SEK -31.8 (-78.4) million.
Liquid assets and short-term investments totaled SEK 158.5 (357.1) million at the period end.
January – September
Financial summary
Net turnover amounted to SEK 7.3 (10.3) million.
The loss before interest, tax, depreciation and amortization (EBITDA) totaled SEK -88.6 (-229.8) million. Basic and diluted earnings per share amounted to SEK -3.76 (-9.88) and SEK -3.76 (-9.88) respectively.
Cash flow from operating activities amounted to SEK -125.3 (-248.1) million.
Liquid assets and short-term investments totaled SEK 158.5 (357.1) million at the period end.
Significant events after the quarter
The first patient was included in a phase I study in which the safety and tolerability of a combination of birinapant and radiotherapy are evaluated in patients with recurrent epithelial cancer in the head and neck region. The study is sponsored and funded as part of the National Cancer Institute’s Cancer Treatment Evaluation Program (CTEP).
The first milestone-payment for the candidate drug MIV-701 in veterinary medicine was received in October.
Preclinical data showing that in addition to its direct effect on cancer cells, MIV-818 also modulates the anti-tumor immune response, presented at the AACR (Free AACR Whitepaper)-NCI-EORTC conference in Boston.
The ninth and final liver cancer patient was included in the phase Ia study with MIV-818. Based on safety and tolerability as well as pharmacokinetics and positive biomarker data, it was decided to initiate the phase Ib portion of the study.
Conference call for investors, analysts and the media
The Interim Report January – September 2019 will be presented by Medivir’s President & CEO, Uli Hacksell.
Time: Wednesday, November 27, 2019, at 14.00 (CET).